Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), joined partner The Chopra Foundation in recognizing World Mental Health Day, which was Monday, Oct. 11, 2022. The two organizations are working together to research the potential of psychedelic-based therapies for the treatment of mental health and to provide education about … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN), The Chopra Foundation Note World Mental Health Day”
Cybin (NYSE American: CYBN) (NEO: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(R), today provided an update on its intellectual property (“IP”) progress in support of its research and development strategy. According to the update, Cybin continues to prioritize the development of in-house IP and licensing opportunities that support its active development programs … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) ‘Focused on Adding Targeted IP’”
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), and its wholly owned subsidiary, Cybin IRL Limited, have signed a deal with Mindset Pharma Inc. (CSE: MSET) (FSE: 9DF) (OTCQB: MSSTF) to acquire an exclusive license to an extensive targeted class of tryptamine-based molecules. The agreement for the license will … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Enters Agreement to Obtain Novel Catalog of Psychedelic-Based Compounds”
Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced its participation in upcoming conferences taking place in September and October 2022. The company’s CEO Doug Drysdale participated in a panel discussion titled “Trials to Treatments” at the Interdisciplinary Conference on Psychedelic Research, Psychedelic Science, … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Announces Participation in Upcoming Scientific and Investor Conferences”
Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has successfully reached key research and development (“R&D”) milestones that were identified in the company’s acquisition agreement of Adelia Therapeutics in 2020. The milestones were reached faster than expected, and have helped Cybin make progress on its path toward clinical drug … Continue reading “NetworkNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Announces R&B Milestones, Beats Anticipated Timeframe”
First dose is administered as first-ever novel psilocybin analog enters clinical development Cybin believes CYB003 has potential to successfully address the challenges and limitations of oral psilocybin The high level of participant interest in the study indicates a significant unmet need for alternative treatment options for major depressive disorder (“MDD”) Cybin (NEO: CYBN) (NYSE American: CYBN) … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Clinical Trial Marks ‘Tremendous’ Milestone as First Participants Receive Initial CYB003 Dose”
Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, is making significant headway with its flagship deuterated psilocybin analog, CYB003. “CYB003 has the potential to effectively treat alcohol use disorder (‘AUD’) and major depressive disorder (‘MDD’). The substance is designed to achieve … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Marking Industry’s First-Ever Entry of Novel Psilocybin Analog into Clinical Development”
Cybin (NYSE American: CYBN) (NEO: CYBN) is a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions. The company is on the leading edge of a transformation that has seen the status of psilocybin evolve as a result of mounting public acceptance and growing evidence that the substance delivers … Continue reading “NetworkNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) on Leading Edge of Psilocybin Research”
Cybin (NYSE American: CYBN) (NEO: CYBN) is a biotechnology company focused on progressing Psychedelics to Therapeutics(TM). The company today announced that its wholly controlled subsidiary, Adelia Therapeutics Inc., has achieved the milestone identified as Y2, Q4(ii) as contemplated by the terms of a contribution agreement dated Dec. 4, 2020, among Cybin, Cybin Corp., Cybin US … Continue reading “NetworkNewsBreaks – Cybin Inc.’s (NYSE American: CYBN) (NEO: CYBN) Adelia Marks Final Development Milestone”
A new study shows promise in treating alcohol addiction with psychedelic mushroom compound, psilocybin These results align with efforts and expectations of Cybin, a leading ethical biopharmaceutical company championing psilocybin After receiving FDA approval, the company is moving forward with a first-in-human clinical trial evaluating CYB003 A new study published in JAMA Psychiatry offers hope … Continue reading “Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Pioneering Efforts as Studies, Research Show Psilocybin’s Potential in Treating AUD”
